THE PAST 25 YEARS has witnessed an enthusiastic awakening of interest in the problem of cerebral vascular diseases. The demonstration that arteriosclerotic lesions of the extracranial arteries were frequently responsible for strokes1-3 led directly to an appreciation of the significance of certain symptoms and signs in diagnosis, as well as to a more dynamic classification of stroke, which focused upon pathogenesis and management (transient ischemic attack, progressing stroke and completed stroke) and to carotid endarterectomy as a means of preventing cerebral infarction.4-7 Simultaneously, medical prophylaxis of cerebral infarction by anticoagulation was described.8"-This form of therapy remains controversial despite many published studies."1-23 Evaluation of therapy required studies on the natural history of the various types of occlusive and hemorrhagic cerebral vascular diseases; though difficult to interpret, these studies sharpened our understanding of the clinical and pathologic problem.24 33 Epidemiologic studies gradually identified a few obvious risk factors in cerebral vascular disease34-36 similar to those in arteriosclerotic heart disease that eventually resulted in a modestly successful campaign against hypertension, which is clearly the most important risk factor,34-38 as well as an endorsement of dietary weight control and increased physical activity.
There now appears to be evidence that modest inroads have been made in reducing the number of cerebral infractions by means of the various modalities described above, as well as by the use of drugs that inhibit platelet agglutination.39-47 Despite these hard-won achievements, the number of patients with cerebral infarction continues to increase with the age of the population. It is now apparent that, short of finding a means of eliminating atherosclerosis, hypertension and valvular heart disease, the number of patients with symptomatic cerebral vascular diseases will continue to increase. It is also clear that our ability to treat the patient who has already had a "stroke" has not improved measurably in the past 25 years, although there have been benefits of better nursing care, more sophisticated life-system monitoring techniques and improved medical management of the various systemic disorders that frequently coexist in the patient with stroke. The true clinical problem is proper management of cerebral ischemia to prevent ischemia from becoming infarction.
Insight into the biology of cerebral ischemia has been acquired from studies of patients with strokes and from animal models of cerebral ischemia. Progressively more definitive means of studying cerebral blood flow, biochemical measurements on ischemic brain tissue, histochemical and immunofluorescent staining techniques, electron microscopy and electrophysiologic measurements have resulted in a better understanding of the biology of cerebral ischemia. Studies using these techniques have begun to permit some insight into the sequence of events in cerebral ischemia, and have afforded an opportunity to devise pharmacologic techniques to influence those events. This has been achieved together with an enormously improved understanding of normal cerebral circulatory and metabolic functions, their controls and how they are affected by disease. 48 The circulatory physiologic events in cerebral ischemia have been well documented and can be reviewed briefly: 1) Cerebral blood flow (CBF) is reduced in the center of the infarct and increased in the surrounding ischemic zone. The hyperemia (sometimes termed "'luxury perfusion") is secondary to increased H+ ion concentration in brain parenchyma from lactic acid and CO.49-65 2) Autoregulation is impaired, resulting in predict- 5) There is a significant impairment of cerebral recirculation after ischemia (no-reflow phenomenon) due to swelling of capillary endothelium, swelling of perivascular glia and increased blood viscosity due to coagulopathy.86-94 6) Tissue survival during total ischemia is enhanced by washing out residual blood in cerebral vessels at the onset of ischemia.9' 102 Though the mechanism for this is not understood, it suggests that one deleterious effect of ischemia may be an accumulation of "toxic" substance rather than substrate deficiency alone.
The sequence of many biochemical and histologic events in ischemia has also been established from experimental stroke models. Experimental limitations relate specifically to the necessity of immobilizing all cerebral metabolic and enzymatic activity instantaneously. A perfect model does not yet exist, and modalities for stopping tissue metabolic activity are under intensive study. A solution will provide a quantum leap in stroke research.
The evidence suggests that cerebral ischemia initiates events that defer the stage of irreversible injury. Vascular The above observations have stimulated the development of strategies aimed at enhancing tissue survival by decreasing those metabolic activities involved in cell function so that sufficient energy potential will remain to preserve cell membrane integrity and prevent cell autolysis.
Evidence demonstrates that barbiturates reduce the extent of experimental infarction, an effect that may have direct clinical applicability.'16-158 The mechanisms responsible for this protective effect have been the subject of much interest and study. Several explanations have been suggested: 1) improvement of CBF and brain glucose use in stage of recirculation;159 2) no relation to reduced energy requirements of the tissues;'60 and 3) prevention of the initiation of the chain-spreading, free-radical reactions.'61' 162 Other drugs, such as reserpine, which depletes tissue stores of monoamines, and aminophylline, which inhibits the ischemia-induced rise of cAMP, are also effective in favorably altering the biochemical evidences of progressing ischemia,163 but there have been no corroborative clinical trials.
Interest has been focused on the concept that ischemic brain damage is not so much a function of substrate deprivation as it is an effect of "toxic substances" in the ischemic tissue. It has been suggested that the central nervous system is particularly susceptible to free-radical degenerative processes,'61 162, 64 165 because membrane lipids undergo pathologic freeradical reactions in the presence of oxygen. The lipid damage is catalyzed by derivatives from mitochondrial and endoplasmic reticulum electron transport systems and extravasated red blood cells. These hypotheses, which represent a radical departure from the traditional view of the mechanism of tissue damage in ischemia, await experimental confirmation. Treatment of atherosclerosis and hypertension has changed dramatically since Sir George made that statement. Therapeutic evaluation has improved since then, but much improvement lies ahead, and the attitudes against systematic assessment of therapeutic safety and efficacy still persist, though they are not as strong as in the 1940s.
The history of clinical trials is temporally parallel to the history of the National Heart, Lung, and Blood Institute (NHLBI) and the American Heart Association (AHA). The first paper that fully described methodologic 
